Abstract
Transarterial Radioembolization (TARE) with 90Y microspheres is used for treatment of liver tumors, including neuroendocrine tumor (NET) liver metastases. Hepatotoxicity is a concern in NET patients receiving TARE, due to longer survival and exposure to additional radioactive therapies. The body surface area (BSA) method for prescribing 90Y resin microspheres may under- or overestimate the ideal administered activity, resulting in radiation doses that may undertreat tumors or over-expose normal liver.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
